PLTT — Pilot Therapeutics Holdings Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 1998 | 1999 | 2000 | 2001 | 2002 | 2003E | 2004E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pilot Therapeutics Holdings, Inc. is a holding company for Pilot Therapeutics, Inc. and is a specialty pharmaceutical company. Through lipid profiling and metabolism, the Company has developed a proprietary, lipid and genomic profiling research platform, termed Functional Liponomics. Using Functional Liponomics, the Company is developing novel, branded, therapeutic, pharmaceutical and over-the-counter (OTC) medical food products that are specifically designed to address dysfunctional lipid metabolism in chronic human diseases such as asthma, coronary heart disease, allergic rhinitis, cancer, cystic acne and rheumatoid arthritis. Pilot expects to launch its first product, Airozin, for adults and children regionally in April 2003 and nationally by 2004.
Directors
- Terrance Little CHM
- Keith Wakeman PRE
- Ross Consaul CEO
- Steven Greenberg CFO
- Floyd Chilton CTO (50)
- Scott Derks VOP
- John Crain OTH (61)
- Jack Voller OTH (62)
- Santo Costa DRC (75)
- James Johnston DRC (70)
- Bradley Undem DRC (52)
- Margaret Urquhart DRC (58)
- Last Annual
- December 31st, 2002
- Last Interim
- June 30th, 2003
- Incorporated
- October 9th, 2001
- Public Since
- April 3rd, 2000
- No. of Shareholders
- 326
- No. of Employees
- 14
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 11,544,501
- Address
- 101 N. Chestnut Street, Suite 102, WINSTON SALEM, 27101
- Web
- Phone
- +1 3367252222
- Auditors
- Ernst & Young LLP
Similar to PLTT
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 22:40 UTC, shares in Pilot Therapeutics Holdings are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Pilot Therapeutics Holdings last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Pilot Therapeutics Holdings share price has underperformed the S&P500 Index by -15.6% over the past year.
There is no consensus recommendation for this security.
Pilot Therapeutics Holdings does not currently pay a dividend.
Pilot Therapeutics Holdings does not currently pay a dividend.
Pilot Therapeutics Holdings does not currently pay a dividend.
To buy shares in Pilot Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Pilot Therapeutics Holdings had a market capitalisation of .
Here are the trading details for Pilot Therapeutics Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PLTT
Based on an overall assessment of its quality, value and momentum Pilot Therapeutics Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pilot Therapeutics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -11.63%.
As of the last closing price of $0.00, shares in Pilot Therapeutics Holdings were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pilot Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pilot Therapeutics Holdings' management team is headed by:
- Terrance Little - CHM
- Keith Wakeman - PRE
- Ross Consaul - CEO
- Steven Greenberg - CFO
- Floyd Chilton - CTO
- Scott Derks - VOP
- John Crain - OTH
- Jack Voller - OTH
- Santo Costa - DRC
- James Johnston - DRC
- Bradley Undem - DRC
- Margaret Urquhart - DRC